SCHEMBL175424

SCHEMBL175424

O=C(CBr)c1ccc2c(c1)OCO2

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTNNB1 P35222 8/20 0.64
WNT3A P56704 8/20 0.64
ALDH1A1 P00352 3/20 0.62
MAPK1 P28482 1/20 0.62
MEN1 O00255 2/20 0.62
KMT2A Q03164 2/20 0.62
MAOB P27338 3/20 0.59
HPGD P15428 1/20 0.56
KDM4E B2RXH2 1/20 0.56
MAPK9 P45984 1/20 0.56
SRD5A2 P31213 1/20 0.56
ATM Q13315 1/20 0.56
HDAC3 O15379 1/20 0.54
HDAC4 P56524 1/20 0.54
HDAC1 Q13547 1/20 0.54
HDAC7 Q8WUI4 1/20 0.54
HDAC2 Q92769 1/20 0.54
HDAC10 Q969S8 1/20 0.54
HDAC11 Q96DB2 1/20 0.54
HDAC8 Q9BY41 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL627847 0.89 ATM (0.70) CTNNB1WNT3AALDH1A1MAPK1HPGD
SCHEMBL22651304 0.86 CTNNB1 (0.69) CTNNB1WNT3AALDH1A1MAPK1MEN1
SCHEMBL2985748 0.86 ALDH1A1 (0.68) CTNNB1WNT3AALDH1A1KMT2AHPGD
SCHEMBL2237626 0.85 MEN1 (0.76) CTNNB1WNT3AALDH1A1MAPK1MEN1
SCHEMBL29458253 0.85 MEN1 (0.76) CTNNB1WNT3AALDH1A1MAPK1MEN1
SCHEMBL6486626 0.84 CTNNB1 (0.66) CTNNB1WNT3AALDH1A1MAPK1MEN1
SCHEMBL4865452 0.84 CTNNB1 (0.66) CTNNB1WNT3AALDH1A1MAPK1MEN1
SCHEMBL7385092 0.82 ALDH1A1 (0.64) CTNNB1WNT3AALDH1A1MAPK1MEN1
SCHEMBL2843731 0.82 CTNNB1 (0.64) CTNNB1WNT3AALDH1A1MAPK1MEN1
SCHEMBL4258312 0.82 CTNNB1 (0.64) CTNNB1WNT3AALDH1A1MAPK1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 236 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3704105-B9 ANTIBACTERIAL COMPOUNDS DISCUVA LTD (GB) 2025-03-05 EP disclosed
EP-3704105-B1 ANTIBACTERIAL COMPOUNDS DISCUVA LTD (GB) 2024-10-16 EP disclosed
EP-4368184-A2 NOVEL COMPOUNDS FOR THE DIAGNOSIS, TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH THE AGGREGATION OF ALPHA-SYNUCLEIN Modag GmbH (DE) 2024-05-15 EP disclosed
US-11680062-B2 3,4-methylenedioxyphenylimidazolylethanonexime ether derivative, preparation method and use thereof, and drug for the treatment of Alzheimer's disease NORTHWEST A & F UNIVERSITY (CN) 2023-06-20 US disclosed
US-11680062-B2 3,4-methylenedioxyphenylimidazolylethanonexime ether derivative, preparation method and use thereof, and drug for the treatment of Alzheimer's disease NORTHWEST A & F UNIVERSITY (CN) 2023-06-20 US disclosed
US-11680062-B2 3,4-methylenedioxyphenylimidazolylethanonexime ether derivative, preparation method and use thereof, and drug for the treatment of Alzheimer's disease NORTHWEST A & F UNIVERSITY (CN) 2023-06-20 US disclosed
US-20230159503-A1 3,4-METHYLENEDIOXYPHENYLIMIDAZOLYLETHANONEXIME ETHER DERIVATIVE, PREPARATION METHOD AND USE THEREOF, AND DRUG FOR THE TREATMENT OF ALZHEIMER'S DISEASE NORTHWEST A & F UNIVERSITY (CN) 2023-05-25 US disclosed
US-20230159503-A1 3,4-METHYLENEDIOXYPHENYLIMIDAZOLYLETHANONEXIME ETHER DERIVATIVE, PREPARATION METHOD AND USE THEREOF, AND DRUG FOR THE TREATMENT OF ALZHEIMER'S DISEASE NORTHWEST A & F UNIVERSITY (CN) 2023-05-25 US disclosed
US-20230159503-A1 3,4-METHYLENEDIOXYPHENYLIMIDAZOLYLETHANONEXIME ETHER DERIVATIVE, PREPARATION METHOD AND USE THEREOF, AND DRUG FOR THE TREATMENT OF ALZHEIMER'S DISEASE NORTHWEST A & F UNIVERSITY (CN) 2023-05-25 US disclosed
US-20230067910-A1 NOVEL COMPOUNDS FOR THE DIAGNOSIS, TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH THE AGGREGATION OF ALPHA-SYNUCLEIN MODAG GMBH (DE) 2023-03-02 US disclosed
US-5717116-A TREATING A MIXTURE OF PHENYLHALOGENOMETHYLCARBINOLS WITH A LIPASE IN THE PRESENCE OF A CARBOXYLATE FOLLOWED BY CYCLIZATION WITH A BASE SUMIKA FINE CHEMICALS COMPANY, LIMITED (JP) 1998-02-10 US disclosed
EP-0735142-A2 Process for producing (R)-styrene oxides SUMIKA FINE CHEMICAL COMPANY, LTD. (JP) 1996-10-02 EP disclosed
EP-0350251-B1 N-Substituted amide derivatives TAISHO PHARMACEUTICAL CO LTD (JP) 1994-03-16 EP disclosed
US-4937360-A N-substituted amide derivatives useful for treating liver diseases TAISHO PHARMACEUTICAL CO., LTD. (JP) 1990-06-26 US disclosed
EP-0350251-A2 N-Substituted amide derivatives TAISHO PHARMACEUTICAL CO. LTD (JP) 1990-01-10 EP disclosed
US-4684739-A HYPOTENSIVE AGENTS MITSUBISHI CHEMICAL INDUSTRIES LIMITED (JP) 1987-08-04 US disclosed
EP-0054304-B1 ALKYLENEDIOXYBENZENE DERIVATIVES, ACID ADDITION SALTS THEREOF AND A METHOD FOR THEIR PREPARATION MITSUBISHI KASEI CORPORATION (JP) 1984-08-15 EP disclosed
US-4446141-A Hypotensive piperidine derivatives KYOWA HAKKO KOGYO CO. (JP) 1984-05-01 US disclosed
EP-0018417-B1 NOVEL PIPERIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM KYOWA HAKKO KOGYO CO., LTD (JP) 1982-06-30 EP disclosed
EP-0018417-A1 Novel piperidine derivatives and pharmaceutical compositions containing them KYOWA HAKKO KOGYO CO., LTD (JP) 1980-11-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230067910-A1 NOVEL COMPOUNDS FOR THE DIAGNOSIS, TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH THE AGGREGATION OF ALPHA-SYNUCLEIN SNCA, PARK7, SYNCRIP CTNNB1 2069/4885WNT3A 2822/4885ALDH1A1 950/4885
US-20230159503-A1 3,4-METHYLENEDIOXYPHENYLIMIDAZOLYLETHANONEXIME ETHER DERIVATIVE, PREPARATION METHOD AND USE THEREOF, AND DRUG FOR THE TREATMENT OF ALZHEIMER'S DISEASE NOS3, CYP51A1, NOS1 CTNNB1 2714/4885WNT3A 588/4885ALDH1A1 1852/4885
US-11680062-B2 3,4-methylenedioxyphenylimidazolylethanonexime ether derivative, preparation method and use thereof, and drug for the treatment of Alzheimer's disease NOS3, CYP51A1, NOS1 CTNNB1 2714/4885WNT3A 588/4885ALDH1A1 1852/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.